Eli Lilly Reportable Segment — Equity Method Investments decreased by 15.1% to $33.80M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 88.2%, from $285.68M to $33.80M.
An increase indicates ongoing investment in strategic partnerships, while a decrease may signal divestment or impairment.
Represents the carrying value of investments in entities where the segment holds significant influence but not control....
Commonly reported by large pharmaceutical firms engaged in collaborative drug development.
lly_segment_reportable_segment_equity_method_investments| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $240.58M | $240.58M | $240.58M | $240.58M | $285.68M | $285.68M | $285.68M | $285.68M | $1.15B | $39.80M | $33.80M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +18.7% | +0.0% | +0.0% | +0.0% | +302.1% | -96.5% | -15.1% |
| YoY Change | — | — | — | — | +18.7% | +18.7% | +18.7% | +18.7% | +302.1% | -86.1% | -88.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.